The sell-off followed the company’s revised guidance for 2026, which anticipates a market value growth rate of just 2% to 4%. Demant characterized the figure as a conservative assumption driven by general macroeconomic uncertainty. This forecast sits below the company’s long-term targets, prompting analysts at Jefferies to note that investor appetite for the consumer healthcare sector remains notably low. Shares fell to 193.50 Danish kroner in afternoon trading, extending a year-to-date decline of over 11%.
Missed Expectations and Currency Headwinds
For the current year, the company expects adjusted earnings before interest and taxes (EBIT) to land between 4.10 billion and 4.50 billion kroner ($647.3 million to $710.5 million). This range trails the 4.65 billion kroner projected by market analysts. Demant also flagged a potential 2% earnings headwind caused by exchange-rate volatility, while organic growth is now estimated between 3% and 6%, trailing the consensus expectation of 5%.
Comments (0)
No comments yet. Be the first!